Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus VERELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus VERELAN.
AFEDITAB CR vs VERELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Verapamil inhibits calcium ion influx across cardiac and smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and negative chronotropic, dromotropic, and inotropic effects.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Hypertension: 120-240 mg ER orally once daily; maximum 480 mg/day. Angina: 80-120 mg IR orally three times daily; ER 180-360 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Terminal elimination half-life is 2.8 to 7.4 hours in healthy adults, prolonged in hepatic impairment or elderly (up to 12 hours).
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal excretion accounts for approximately 70% of elimination, with 3-4% as unchanged drug. Fecal elimination accounts for about 25%, predominantly via biliary secretion.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker